JMI Equity — 2023 Investments

2 investments dated 2023 · listed companies and verified rows first · show all

Ensomaensoma.comSeries B · Jan 2023 · $85M

Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.

BiotechHealthtechMedical DevicesBoston, US

Albert Seymour(Director)

BoardKush Parmar(Executive Officer, Director)inPaula Soteropoulos(Director)Stephen Knight(Director)in

Co-investors5AM Ventures Aju IB Investment Catalio Capital Management, LP Delos Capital F-Prime Capital Solasta Ventures +10 more

Evommuneevommune.com inSeries B · Apr 2023 · $50M

Evommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief.

BiotechHealthtechPalo Alto, US

Luis Pena(President & Chief Executive Officer)inJanice Drew(Executive Officer)David Cohen(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)

Co-investorsAndera Partners Avego BioScience Capital B Capital Group B4 Capital Beiersdorf Innovation Fund FemHealth Ventures +4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.